The role of dupilumab in diverse allergic pathologies
DOI:
https://doi.org/10.36105/psrua.2023v2n5.03Keywords:
dupilumab, atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis, asthmaAbstract
Allergic responses represent a significant health problem due to the ineffectiveness of current treatments, as they attempt to decrease the immune response triggered but are unable to create immune memory that reduces the intensity of such response, so the intensity of the response will always be the same as the first time. An allergic response is characterized by the exacerbated and prolonged release of immunoglobulin E (IgE) that triggers innate immune responses due to the activation of T lymphocytes towards a Th2 phenotype, responsible for the release of interleukins 3 and 4 (IL-3 and IL-4), and the activation of B lymphocytes towards IgE-producing plasma cells. Currently, monoclonal antibodies (mAbs) are used as treatment for various allergic pathologies as they can be used to inhibit the signaling pathways of various interleukins, inactivating the differentiation of T lymphocytes, B lymphocytes, and the production of IgE. One of the most versatile mAbs in the treatment of various allergic responses is Dupilumab, which is designed to inhibit the signaling chain of IL-3 and IL-4, more specifically, it binds to the α receptor of IL-4 and the cytokine-induced receptor complex IL-13. Dupilumab inhibits IL-4 and IL-13 through receptor 1, stopping the release of IgE and proinflammatory cytokines. This treatment can be used to control the inflammatory response caused by allergens. On the other hand, the use of Dupilumab is not patented as the treatment of choice for allergic pathologies. Therefore, in this review, we compile the results of clinical studies of Dupilumab and other mAbs in atopic dermatitis (AD), eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), and asthma, with the aim of determining which of the mAbs has provided better results.
Downloads
PLUMX metrics
References
Kim J., Yi M., & Yong T. Allergen-like Molecules from Parasites. Current protein & peptide science. 2020;21(2), 186–202. https://doi.org/10.2174/138920372066619070815430 DOI: https://doi.org/10.2174/1389203720666190708154300
Mejía D., Salvatierra G., Maximiliano J., Rímac R., Carhuaricra D., Almeyda M., et al . Expresión de citoquinas Th1 (IL-2, IL-12, IFN-γ, TNF-α), Th2 (IL-4, IL-10, TGF-β) y Th17 (IL-17) en linfocitos circulantes de cuyes inoculados con una cepa de campo de Salmonella Typhimurium. Rev. investig. vet. Perú. 2019 Oct; 30( 4 ): 1750-1761. http://dx.doi.org/10.15381/rivep.v30i4.17188 DOI: https://doi.org/10.15381/rivep.v30i4.17188
Shamoun L., Skarstedt M., Andersson R., Wagsater D., Dimberg J. Association study on IL-4, IL-4Ralpha and IL-13 genetic polymorphisms in Swedish patients with colorectal cancer. Clin Chim Acta. 2018;487:101–106. DOI: https://doi.org/10.1016/j.cca.2018.09.024
Harb H. and Chatila T. Mechanisms of Dupilumab. Clin Exp Allergy. 2020 January; 50(1): 5–14. http://dx.doi.org/10.1111/cea.13491 DOI: https://doi.org/10.1111/cea.13491
Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol [Internet]. 2006 [cited 2022 Sep 16];24(1):607–56. Available from: https://pubmed.ncbi.nlm.nih.gov/16551261/ DOI: https://doi.org/10.1146/annurev.immunol.23.021704.115821
Punt J., Stranford S., Jones P., and Owen J. Capítulo 15: Alergia, hipersensibilidad e inflamación crónica. In KUBY. Inmunología, 8e. 2022. Available from: https://accessmedicina.mhmedical.com/content.aspx?sectionid=249661284&bookid=2951&Resultclick=2
Eichenfield, LF., Tom, WL., Chamlin, SL., Feldman, SR., Hanifin, JM., Simpson, EL., et al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis Work Group. J Am Acad Dermatol. 2014; 70(2):338–51. DOI: https://doi.org/10.1016/j.jaad.2013.10.010
Junttila IS. Tuning the cytokine responses: An update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol [Internet]. 2018 [cited 2022 Sep 16];9. http://dx.doi.org/10.3389/fimmu.2018.00888 DOI: https://doi.org/10.3389/fimmu.2018.00888
Widuri A. Correlación entre la expresión de interleucina 4 y la sensibilización a alérgenos en pacientes con rinitis alérgica. Rev. alerg. Méx. 2021; 68( 2 ): 89-93. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2448-91902021000200089&lng=es. Epub 01-Nov-2021.
Sroka J., Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. International Journal of Molecular Sciences. En t. J. Mol. ciencia 2021 , 22 (8), 4130; https://doi.org/10.3390/ijms22084130 DOI: https://doi.org/10.3390/ijms22084130
Wraith DC, Krishna MT. Peptide allergen-specific immunotherapy for allergic airway diseases-State of the art. Clin Exp Allergy [Internet]. 2021;51(6):751–69. http://dx.doi.org/10.1111/cea.13840 DOI: https://doi.org/10.1111/cea.13840
Querol Nasarre I.. Dermatitis atópica. Rev Pediatr Aten Primaria [Internet]. 2009 Dic [citado 2022 Dic 21] ; 11( Suppl 17 ): 317-329. DOI: https://doi.org/10.4321/S1139-76322009000700003
Vázquez D, Onetti CI, Parisi CA, Martínez JC, Croce J, Moreno P, García M, Ivancevich JC, Gómez RM. Tratamiento de la rinitis alérgica en pediatría en Argentina. Documento de actualización [Allergic rhinitis' treatment in children in Argentina. Update]. Rev Alerg Mex. 2020;67 Suppl 1:S1-S28. Spanish. http://dx.doi.org/10.29262/ram.v67i0.649 DOI: https://doi.org/10.29262/ram.v67i0.649
Duff AL, Platts-Mills TA. Allergens and asthma. Pediatr Clin North Am. 1992 Dec;39(6):1277-91. http://dx.doi.org/10.1016/s0031-3955(16)38445-0 DOI: https://doi.org/10.1016/S0031-3955(16)38445-0
Armisén M., Vidal C., López-Rosés L., Rodríguez V., Bartolomé B.. Esofagitis eosinofílica por sensibilización a proteínas de leche de cabra y oveja. Rev. esp. enferm. dig. [Internet]. 2008 Ene [citado 2022 Dic 21] ; 100( 1 ): 53-56. DOI: https://doi.org/10.4321/S1130-01082008000100011
Ballart, M., Monrroy, H., Iruretagoyena, M., Parada, A., Torres, J., & Espino, A. Esofagitis eosinofílica: diagnóstico y manejo [Diagnosis and management of eosinophilic esophagitis]. Revista médica de Chile, 2020;148(6), 831–841.
https://doi.org/10.4067/S0034-98872020000600831 DOI: https://doi.org/10.4067/S0034-98872020000600831
Lucendo, A., & Molina-Infante, J. Eosinophilic oesophagitis: Current evidence-based diagnosis and treatment. Esofagitis eosinofílica: diagnóstico y tratamiento actual basado en la evidencia. Gastroenterologia y hepatologia, 2018; 41(4), 281–291. https://doi.org/10.1016/j.gastrohep.2017.12.007 DOI: https://doi.org/10.1016/j.gastrohep.2017.12.007
Navarro P., Arias Á., Arias-González L., Laserna-Mendieta E., Ruiz-Ponce M., & Lucendo A. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment pharmacology & therapeutics, 2019;49(9), 1116–1125. https://doi.org/10.1111/apt.15231 DOI: https://doi.org/10.1111/apt.15231
Alexander E.S., Martin L.J., Collins M.H., Kottyan L.C., Sucha- rew H., He H., et al. Twin and family studies reveal strong environmental and weaker genetic cues explaining herita- bility of eosinophilic esophagitis. J Allergy Clin Immunol. 2014;134:1084-92.e1. DOI: https://doi.org/10.1016/j.jaci.2014.07.021
Egritas Gurkan O., Ozturk H., Karagol H., Ceylan K., Duztas D. T., Ekinci O., et al. Primary Eosinophilic Gastrointestinal Diseases Beyond Eosinophilic Esophagitis in Children. Journal of pediatric gastroenterology and nutrition. 2021; 72(2): 294–299. https://doi.org/10.1097/MPG.000000000000292 DOI: https://doi.org/10.1097/MPG.0000000000002925
Dellon E., Kim H., Sperry S., Rybnicek D., Woosley J., Shaheen N. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79:577-85.e4 DOI: https://doi.org/10.1016/j.gie.2013.10.027
Kaur S., Rosen J., Kriegermeier A., Wechsler J., Kagalwalla A., Brown J. Utility of gastric and duodenal biopsies during follow-up endoscopy in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2017;65:399-403. DOI: https://doi.org/10.1097/MPG.0000000000001528
Ahmed, M., Mansoor, N., & Mansoor, T. (2021). Review of eosinophilic oesophagitis in children and young people. European journal of pediatrics, 180(12), 3471–3475. https://doi.org/10.1007/s00431-021-04174-0 DOI: https://doi.org/10.1007/s00431-021-04174-0
Lucendo A., Arias A., and Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: A syste- matic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:13-22.e1. DOI: https://doi.org/10.1016/j.cgh.2015.07.041
Golekoh M., Hornung L., Mukkada V., Khoury J., Putnam P., Backeljauw P. Adrenal insufficiency after chronic swallowed glucocorticoid therapy for eosinophilic esophagitis. J Pediatr. 2016;170:240-5. DOI: https://doi.org/10.1016/j.jpeds.2015.11.026
Cianferoni A. (2020). Non-IgE Mediated Food Allergy. Current pediatric reviews, 16(2), 95–105. https://doi.org/10.2174/1573396315666191031103714 DOI: https://doi.org/10.2174/157339631566619103110371
Kliewer K. L., Cassin A. M., & Venter C. Dietary Therapy for Eosinophilic Esophagitis: Elimination and Reintroduction. Clinical reviews in allergy & immunology. 2018; 55(1): 70–87. https://doi.org/10.1007/s12016-017-8660-1 DOI: https://doi.org/10.1007/s12016-017-8660-1
Lucendo A., Molina-Infante J., Arias A., Von Arnim U., Bre- denoord A., Bussmann C, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5:335-58. DOI: https://doi.org/10.1177/2050640616689525
Moawad F., Molina-Infante J., Lucendo A., Cantrell S., Tma- nova L., Douglas K. Systematic review with meta-analysis: Endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46:96-105. DOI: https://doi.org/10.1111/apt.14123
Furuta GT, Atkins FD, Lee NA, Lee JJ (2014) Changing roles of eosinophils in health and disease. Ann Allergy Asthma Immunol 113(1):3–8. https://doi.org/10.1016/j.anai.2014.04.002 DOI: https://doi.org/10.1016/j.anai.2014.04.002
Hassani M., & Koenderman L. Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview. Allergy, 2018; 73(10): 1979–1988. https://doi.org/10.1111/all.13451 DOI: https://doi.org/10.1111/all.13451
Harish A., & Schwartz S. A. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions. Clinical reviews in allergy & immunology, 2020;59(2):231–247. https://doi.org/10.1007/s12016-019-08775-4 DOI: https://doi.org/10.1007/s12016-019-08775-4
Spergel JM, Rothenberg ME, Collins MH et al (2012) Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 129(2):456–463, 63.e1–3.
https://doi.org/10.1016/j.jaci.2011.11.044 DOI: https://doi.org/10.1016/j.jaci.2011.11.044
Markowitz JE, Jobe L, Miller M, Frost C, Laney Z, Eke R (2017) Safety and efficacy of Reslizumab for children and adolescents with eosinophilic esophagitis treated over nine years. J Pediatr Gastroenterol Nutr 66:893–897.
https://doi.org/10.1097/MPG.0000000000001840 DOI: https://doi.org/10.1097/MPG.0000000000001840
Ko E, Chehade M. Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand? Clin Rev Allergy Immunol. 2018 Oct;55(2):205-216. http://dx.doi.org/10.1007/s12016-018-8674-3
Yee C., Albuhairi S., Noh E., El-Khoury K., Rezaei S., Abdel-Gadir A., et al. Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab. The journal of allergy and clinical immunology. In practice. 2019; 7(2): 451–461.e7. https://doi.org/10.1016/j.jaip.2018.09.015 DOI: https://doi.org/10.1016/j.jaip.2018.09.015
Ko E., & Chehade M. Biological Therapies for Eosinophilic Esophagitis: Where Do We Stand?. Clinical reviews in allergy & immunology, 2018; 55(2), 205–216. https://doi.org/10.1007/s12016-018-8674-3 DOI: https://doi.org/10.1007/s12016-018-8674-3
Blanchard C, Mingler MK, Vicario M, Abonia JP, Wu YY, Lu TX, Collins MH, Putnam PE, Wells SI, Rothenberg ME (2007) IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J Allergy Clin Immunol 120(6): 1292–1300. https://doi.org/10.1016/j.jaci.2007.10.024 DOI: https://doi.org/10.1016/j.jaci.2007.10.024
Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, Nadeau K, Kaiser S, Peters T, Perez A, Jones I, Arm JP, Strieter RM, Sabo R, Gunawardena KA (2015) Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 135(2):500–507. https://doi.org/10.1016/j.jaci.2014.07.049 DOI: https://doi.org/10.1016/j.jaci.2014.07.049
Dellon E, Collins M, Assouline-Dayan Y et al (2016) A random- ized, double-blind, placebo-controlled trial of a novel recombinant, humanized,anti-interleukin-13 monoclonal antibody (RPC4046) in patients with active eosinophilic esophagitis: results of the HEROES study. American College of Gastroenterology ACG, Las Vegas. DOI: https://doi.org/10.1038/ajg.2016.356
Hirano I, Dellon E, Hamilton J et al (2017) Dupilumab efficacy and safety in adult patients with active eosinophilic esophagitis: a randomized, double blind, placebo controlled phase 2 trial. World Congress of Gastroenterology at ACG, Orlando.
Dowling, Paul J.; Neuhaus, Hannah; Polk, Brooke I. (2018). The Role of the Environment in Eosinophilic Esophagitis. Clinical Reviews in Allergy & Immunology–. http://dx.doi.org/10.1007/s12016-018-8697-9 DOI: https://doi.org/10.1007/s12016-018-8697-9
Herrera-Sánchez D., Hernández-Ojeda M., & Vivas-Rosales, I. Estudio epidemiológico sobre dermatitis atópica en México. Revista alergia Mexico, 2019; 66(2): 192–204. DOI: https://doi.org/10.29262/ram.v66i2.591
Ignacio, J., Gairaud, R. Dermatitis Atópica. Revista Medica De Costa Rica Y Centroamerica Lxxiii 2016; 620: 711-716.
Armario-Hita, J.C., Galán-Gutiérrez, M., & Carrascosa-Carrillo, J.M. Dermatitis atópica. Más Dermatitis atópica (eccema) - Síntomas y causas Dermatología, 2021; 34: 5–14. DOI: https://doi.org/10.5538/1887-5181.2021.34.5
Thomsen, S. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN allergy, 2014; 2014(354250). https://doi.org/10.1155/2014/354250 DOI: https://doi.org/10.1155/2014/354250
Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015;73:311---8. DOI: https://doi.org/10.1016/j.cyto.2014.11.023
D'Ippolito, D., & Pisano, M. Dupilumab (Dupixent): An INTERLEUKIN-4 receptor antagonist FOR atopic dermatitis. P & T : a peer-reviewed journal for formulary management. Drug Forecast. 2018; 43,(9): 532-535. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110636/
Jaume, M.E., Teresa, M., y Pérez, G. Dermatitis atópica. Asociación Española de Pediatría 2019; 2: 161–75.
Grinich E. E., Schmitt J., Küster D., Spuls P. I., Williams H. C., Chalmers J. R., et al. Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative. The British journal of dermatology. 2018; 179(2):540–541. https://doi.org/10.1111/bjd.16732 DOI: https://doi.org/10.1111/bjd.16732
Stable, Y., Zamora, Z. Generalidades de la dermatitis atópica y su vinculación con la respuesta inflamatoria y el estrés oxidativo. Overview of atopic dermatitis and its relationship with the inflammatory response and oxidative stress. Archivos de Alergia e Inmunología Clínica. 2021; 52(1): 13-18.
Seegräber, M., Srour, J., Walter, A., Knop, M., & Wollenberg, A. Dupilumab for treatment of atopic dermatitis. Expert review of clinical pharmacology. 2018; 11(5): 467–474. https://doi.org/10.1080/17512433.2018.1449642 DOI: https://doi.org/10.1080/17512433.2018.1449642
Ahn, C., Huang, W. Clinical Presentation of Atopic Dermatitis [Internet]. Advances in experimental medicine and biology. Springer, Cham. 2017; 1027:p. 39–46. Disponible en: https://link.springer.com/chapter/10.1007/978-3-319-64804-0_4 DOI: https://doi.org/10.1007/978-3-319-64804-0_4
Kim J., Kim B. E., & Leung D. Pathophysiology of atopic dermatitis: Clinical implications. Allergy and asthma proceedings. 2019; 40(2): 84–92. https://doi.org/10.2500/aap.2019.40.4202 DOI: https://doi.org/10.2500/aap.2019.40.4202
Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018;78:S43---52. DOI: https://doi.org/10.1016/j.jaad.2017.11.056
M; S. Dupilumab: First Global Approval [Internet]. Drugs. U.S. National Library of Medicine; 2017 [cited 2021Sep11]. Available from: https://pubmed.ncbi.nlm.nih.gov/28547386/
A study of lebrikizumab in patients with moderate-to-severe atopic dermatitis. Bethesda (MD): ClinicalTrials.gov; 2018 [citado el 22 de febrero]. [Internet]. Disponible en:
https://clinicaltrials.gov/ct2/show/NCT03443024?term=lebrikizumab&cond=Atopic+Dermatitis&rank=1
Donald, BJ., Surani, S., Deol, HS., Mbadugha, UJ., Udeani, G. (2017). Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: Design, development, and potential place in therapy. Drug Des Devel Ther; 11:3559–66. DOI: https://doi.org/10.2147/DDDT.S119545
Sanofi. (2020). FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis. Sanofi. Available from: https://www.sanofi.com/en/media-room/press-releases/2020/2020-05-26-17-40-00
Paller, A., Siegfried, E., Simpson, E., Cork, M., Lockshin, B., Kosloski, M., Kamal, A., et al. (2020, SEPT). A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. Journal of the European Academy of Dermatology and Venereology: JEADV, 35(2), 464–475. https://doi.org/10.1111/jdv.16928 DOI: https://doi.org/10.1111/jdv.16928
Sánchez, A., Sayay, S. (2019). Prevalencia de Dermatitis Atópica en Pre-Escolares. Universidad Nacional de Chimborazo. Disponible en: https://www.medigraphic.com/pdfs/revmedcoscen/rmc-2016/rmc163bc.pdf
Simpson, E., Paller, A., Siegfried, E., Boguniewicz, M., Sher, L., Gooderham, M., Beck, L., Guttman, E., Pariser, D., et al. (2020). Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA dermatology, 156(1), 44–56. https://doi.org/10.1001/jamadermatol.2019.3336 DOI: https://doi.org/10.1001/jamadermatol.2019.3336
Mayo clinic (2021). Dermatitis atópica (eccema). From Mayoclinic.org website: https://www.mayoclinic.org/es-es/diseases-conditions/atopic-dermatitis-eczema/symptoms-causes/syc-20353273
Mishra P, Singh U, Pandey CM, Mishra P, Pandey G. (2019) Application of student's t-test, analysis of variance, and covariance. Ann Card Anaesth; 22:407-11. Disponible en: https://www.annals.in/text.asp?2019/22/4/407/268565 DOI: https://doi.org/10.4103/aca.ACA_94_19
Shirley, M. (2017). Dupilumab: First Global Approval. Drugs, 77(10), 1115–1121. https://doi.org/10.1007/s40265-017-0768-3 DOI: https://doi.org/10.1007/s40265-017-0768-3
Bieber T., et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. Disponible en https://pubmed.ncbi.nlm.nih.gov/33761207/ DOI: https://doi.org/10.1056/NEJMoa2019380
Blauvelt, A., et al. (2017). Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 10;389:2287-2303. http://dx.doi.org/10.1016/S0140-6736(17)31191-1 DOI: https://doi.org/10.1016/S0140-6736(17)31191-1
Paller AS., Siegfried E., et al. (2020, JUN) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol;83(5):1282-1293. http://dx.doi.org/10.1016/j.jaad.2020.06.054 DOI: https://doi.org/10.1016/j.jaad.2020.06.054
Bruin-Weller M., et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to cyclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018 May;178(5):1083-1101. http://dx.doi.org/10.1111/bjd.16156 DOI: https://doi.org/10.1111/bjd.16156
Franken MSS, Garcia OAM, Pabón BD. Actualización del asma. Revista Médica Sinergia. 2021;6(10). DOI: https://doi.org/10.31434/rms.v6i10.717
Gans, M. D., & Gavrilova, T. (2020). Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes. Paediatric respiratory reviews, 36, 118–127. https://doi.org/10.1016/j.prrv.2019.08.002 DOI: https://doi.org/10.1016/j.prrv.2019.08.002
Ramírez-Soto Martín, Bedolla-Barajas Martín, González-Mendoza Tania. Prevalencia de asma, rinitis alérgica y dermatitis atópica en niños escolares en el Bajío de México. Rev. alerg. Méx. [revista en la Internet]. 2018 Dic [citado 2022 Jun 18]; 65(4): 372-378. https://doi.org/10.29262/ram.v65i4.527 DOI: https://doi.org/10.29262/ram.v65i4.527
Arablin-Oropezca SE, González-Uribe V, Del Río-Navarro BE, García-González AC, Navarrete-Rodríguez EM, Valencia A. Dupilumab en el tratamiento del asma. Rev Alerg Mex. 2020 Supl 3:s37-s58.
Asensi Monzó, M. (2017). Crisis de asma. Pediatría Atención Primaria, 19(Supl. 26), 17-25. Recuperado en 29 de junio de 2022, de http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1139-76322017000300002&lng=es&tlng=es
Moral L, Asensi Monzó M, Juliá Benito JC, Ortega Casanueva C, Paniagua Calzón NM, Pérez García MI, et al., Asma en pediatría: consenso REGAP, Anales de Pediatría. 2021;95:125. DOI: https://doi.org/10.1016/j.anpedi.2021.02.009
Rubinsztajn R, Chazan R. Monoclonal Antibodies for the Management of Severe Asthma. Adv Exp Med Biol. 2016;935:35-42. http://dx.doi.org/10.1007/5584_2016_29 DOI: https://doi.org/10.1007/5584_2016_29
Rabe, K. F., Nair, P., Brusselle, G., Maspero, J. F., Castro, M., Sher, L., Zhu, H., Hamilton, J. D., et al. (2018). Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. The New England journal of medicine, 378(26), 2475–2485. https://doi.org/10.1056/NEJMoa1804093 DOI: https://doi.org/10.1056/NEJMoa1804093
Arablin-Oropeza SE, González-Uribe V, Del Río-Navarro BE, García-González AC, Navarrete-Rodríguez EM, Valencia A. Dupilumab en el tratamiento del asma. Rev Alerg Mex. 2020;67 Supl 3:s37-s58. DOI: https://doi.org/10.29262/ram.v67i7.779
Maspero, J. F., Katelaris, C. H., Busse, W. W., Castro, M., Corren, J., Chipps, B. E., Peters, A. T., Pavord, I. D., Ford, L. B., Sher, L., et al. (2020). Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. The journal of allergy and clinical immunology. In practice, 8(2), 527–539.e9. https://doi.org/10.1016/j.jaip.2019.07.016 DOI: https://doi.org/10.1016/j.jaip.2019.07.016
Powell C, Milan SJ, Dwan K, Bax L, Walters N (2015) Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev 7:CD010834. http://dx.doi.org/10.1002/14651858.CD010834.pub2 DOI: https://doi.org/10.1002/14651858.CD010834.pub2
Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015 May;3(5):355-66. http://dx.doi.org/10.1016/S2213-2600(15)00042-9. Epub 2015 Feb 23. Erratum in: Lancet Respir Med. 2015 Apr;3(4):e15. Erratum in: Lancet Respir Med. 2016 Oct;4(10 ):e50. PMID: 25736990. DOI: https://doi.org/10.1016/S2213-2600(15)00042-9
Venancio-Hernández Marco, Mendieta-Flores Elizabeth, Mendiola-Marín Jeannette, Alaniz-Flores Angélica Kathya, Reyes-Arellano Mireya. Abordaje diagnóstico del asma difícil de tratar y asma grave. Rev. alerg. Méx. [Epubt]. 2022 [citado 2022 Jun 18] ; 69( Suppl 1 ): 94-111. https://doi.org/10.29262/ram.v69isupl1.1046 DOI: https://doi.org/10.29262/ram.v69iSupl1.1046
Oralla, R.., & Tercero, J. (2009). Sinusitis crónica. Etiología, clínica y tratamiento. Ámbito Farmacológico. Farmacoterapia. [citado 18 de junio de 2022];3(2):95-101; 28(6), 107-109. Disponible en: https://www.elsevier.es/es-revista-offarm-4-articulo-sinusitis-cronica-etiologia-clinica-tratamiento--13141337
García JA, Carías A, Díaz V. Comportamiento clínico, diagnóstico y tratamiento de la rinosinusitis crónica polipoidea. Otorrinolaringología. 2020;65(4):161-167.
Kristjansson, R. P., Benonisdottir, S., Davidsson, O. B., Oddsson, A., Tragante, V., Sigurdsson, J. K., Stefansdottir, L., Jonsson, S., Jensson, B. O., Arthur, J. G., Arnadottir, G. A., Sulem, G., Halldorsson, B. V., Gunnarsson, B., Halldorsson, G. H., Stefansson, O. A., Oskarsson, G. R., Deaton, A. M., Olafsson, I., Eyjolfsson, G. I., … Stefansson, K. (2019). A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis. Nature genetics, 51(2), 267–276. https://doi.org/10.1038/s41588-018-0314-6 DOI: https://doi.org/10.1038/s41588-018-0314-6
Miranda Cevallos, M. S., Herrera Herrera, P. A., & Vargas Baños, C. E. (2020). Aspectos generales de etiología y tratamiento de la sinusitis crónica. Journal of American Health, 3(2), 95–101. https://doi.org/10.37958/jah.v3i2.37 DOI: https://doi.org/10.37958/jah.v3i2.37
Song, WJ., Lee, JH., Won, HK. et al. Chronic Rhinosinusitis with Nasal Polyps in Older Adults: Clinical Presentation, Pathophysiology, and Comorbidity. Curr Allergy Asthma Rep 19, 46 (2019). https://doi.org/10.1007/s11882-019-0880-4 DOI: https://doi.org/10.1007/s11882-019-0880-4
Fujieda, S., Matsune, S., Takeno, S., Asako, M., Takeuchi, M., Fujita, H., Takahashi, Y., Amin, N., Deniz, Y., Rowe, P., & Mannent, L. (2021). The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan. The Laryngoscope, 131(6), E1770–E1777. https://doi.org/10.1002/lary.29230 DOI: https://doi.org/10.1002/lary.29230
Bachert, C., Han, J. K., Desrosiers, M. Y., Gevaert, P., Heffler, E., Hopkins, C., Tversky, J. R., Barker, P., Cohen, D., Emson, C., et al. (2022). Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. The Journal of allergy and clinical immunology, 149(4), 1309–1317.e12. https://doi.org/10.1016/j.jaci.2021.08.030 DOI: https://doi.org/10.1016/j.jaci.2021.08.030
Hopkins, C., Wagenmann, M., Bachert, C., Desrosiers, M., Han, J. K., Hellings, P. W., Lee, S. E., Msihid, J., Radwan, A., Rowe, P., Amin, N., Deniz, Y., Ortiz, B., Mannent, L. P., & Rout, R. (2021). Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. International forum of allergy & rhinology, 11(7), 1087–1101. https://doi.org/10.1002/alr.22780 DOI: https://doi.org/10.1002/alr.22780
Bachert, C., Hellings, P. W., Mullol, J., Naclerio, R. M., Chao, J., Amin, N., ... & Khan, A. (2019). Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma. The Journal of Allergy and Clinical Immunology: In Practice, 7(7), 2447-2449. https://doi.org/10.1016/j.jaip.2019.03.023 DOI: https://doi.org/10.1016/j.jaip.2019.03.023
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Marquelle Zerecero-Morcksharpea, Catherin Lizeth Reyes Altamirano , Edna Elisa García Vences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All the intellectual content found in this publication is licensed to the consumer public under the figure of Creative Commons©, unless the author of said content has agreed otherwise or limited said faculty to "Proceedings of Scientific Research Universidad Anáhuac. Multidisciplinary Journal of Healthcare©" or "Universidad Anáhuac Mexico©" in writing and expressly.
Proceedings of Scientific Research Universidad Anáhuac. Multidisciplinary Journal of Healthcare is distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The author retains the economic rights without restrictions and guarantees the journal the right to be the first publication of the work. The author is free to publish his article in any other medium, such as an institutional repository.
